EF
CPRX

Empowered Funds’s Catalyst Pharmaceutical CPRX Stock Holding History

Empowered Funds’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.15M Sell
68,536
-33,560
-33% -$990K 0.01% 1152
2026
Q1 		$2.53M Buy
102,096
+6,539
+7% +$156K 0.02% 975
2025
Q4 		$2.23M Buy
+95,557
New +$2.13M 0.04% 452

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Empowered Funds's CPRX Position: Q2 2026 in Review

Empowered Funds reduced its Catalyst Pharmaceutical (CPRX) stake by 33% in Q2 2026, selling an estimated $990K and leaving 68,536 shares worth $2.15M. The position accounts for 0.01% of the portfolio, ranked #1152.

Empowered Funds first reported a position in CPRX in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.53M in Q1 2026. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Empowered Funds held 68,536 shares of Catalyst Pharmaceutical worth $2.15M as of Q2 2026.
  • Empowered Funds sold 33,560 Catalyst Pharmaceutical shares in Q2 2026, an estimated $990K.
  • Catalyst Pharmaceutical made up 0.01% of Empowered Funds's portfolio in Q2 2026, its #1152 holding.
  • Empowered Funds first reported a position in Catalyst Pharmaceutical in Q4 2025 and has held it in 3 quarters since.
  • Empowered Funds's Catalyst Pharmaceutical position peaked at $2.53M in Q1 2026.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Empowered Funds's 13F filing for Q2 2026, filed 17 Aug 2026.